 Inozyme Pharma Inc NASDAQ: INZY has announced preliminary biomarker, safety, and pharmacokinetic PK data from the first three subjects in the Phase 1 portion of its ongoing Phase 12 trial of INZ-701 in ABCC6 Deficiency, which presents as pseudoxanthoma elasticum PXE in older. 